The primary end point is to evaluate the time to progression after gemcitabine alone versus
Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy
in locally advanced pancreatic cancer.
The secondary end points are to evaluate the disease control rate, overall survival time,
toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy
as well as the disease control rate after inductional chemotherapy alone in locally advanced
pancreatic cancer. Translational research including pharmacogenomic study and biomarker study
will also be done concomitantly.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
National Cheng-Kung University Hospital National Taiwan University Hospital